0HFQ.LSE AnaptysBio, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0HFQ.LSE undervalued?
Graham numberThe Graham number of AnaptysBio, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AnaptysBio, Inc. fundamental analysis
No fundamental analysis for AnaptysBio, Inc. yet.
AnaptysBio, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AnaptysBio, Inc.
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agr…
Full company profileFinancial statements of AnaptysBio, Inc. are not available yet.
AnaptysBio, Inc. dividends
AnaptysBio, Inc. has not paid dividends in the last 4 fiscal years.
Who owns AnaptysBio, Inc.
- Insiders 5.63%
- Institutions 94.37%
- Public & others 0.00%
- Free float 20.5M
AnaptysBio, Inc. company profile
- Company name
- AnaptysBio, Inc.
- Ticker
- 0HFQ.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 104
- Fiscal year end
- December
- Address
- 10770 Wateridge Circle, San Diego, CA, United States, 92121
- Phone
- 858 362 6295
- Website
- anaptysbio.com
About AnaptysBio, Inc.
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
AnaptysBio, Inc. management
4- Mr. Daniel R. FagaPresident, CEO & Director · born 1980
- Mr. Christopher M. MurphyChief Financial Officer · born 1984
- Ms. Beth MuellerSenior Vice President of Human Resources
- Mr. Benjamin StoneChief Business Officer · born 1991